APR002 / Apros Therap - LARVOL DELTA

SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Apros Therapeutics, Inc | Trial completion date: Dec 2022 ➔ Jul 2023 | Initiation date: Mar 2022 ➔ Feb 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Apros Therapeutics, Inc

New P1 trial • Infectious Disease • Novel Coronavirus Disease